MedPath
Found 1 clinical trials|View Analysis
Sort by:

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

Phase 3
Recruiting
Conditions
NMDAR Autoimmune Encephalitis
LGI1 Autoimmune Encephalitis
Interventions
Drug: Satralizumab
Other: Placebo
First Posted Date
2022-08-16
Last Posted Date
2025-01-09
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
152
Registration Number
NCT05503264
Locations
🇨🇳

Beijing Tiantan Hospital, Capital Medical University, Beijing, China

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

UC San Diego, La Jolla, California, United States

and more 78 locations
© Copyright 2025. All Rights Reserved by MedPath